Long-Term Outcome after Catheter Ablation of Ventricular Tachycardia in Patients with Nonischemic Dilated Cardiomyopathy

Daniele Muser, Pasquale Santangeli, Simon A. Castro, Rajeev Pathak, Jackson J. Liang, Tatsuya Hayashi, Silvia Magnani, Fermin C. Garcia, Mathew D. Hutchinson, Gregory G. Supple, David S. Frankel, Michael P. Riley, David Lin, Robert D. Schaller, Sanjay Dixit, Erica S. Zado, David J. Callans, Francis E. Marchlinski

Research output: Contribution to journalArticle

65 Citations (Scopus)


Background - Catheter ablation (CA) of ventricular tachycardia (VT) in patients with nonischemic dilated cardiomyopathy can be challenging because of the complexity of underlying substrates. We sought to determine the long-term outcomes of endocardial and adjuvant epicardial CA in nonischemic dilated cardiomyopathy. Methods and Results - We examined 282 consecutive patients (aged 59±15 years, 80% males) with nonischemic dilated cardiomyopathy who underwent CA. Ablation was guided by activation/entrainment mapping for tolerated VT and pacemapping/targeting of abnormal electrograms for unmappable VT. Adjuvant epicardial ablation was performed for recurrent VT or persistent inducibility after endocardial-only ablation. Epicardial ablation was performed in 90 (32%) patients. Before ablation, patients failed a median of 2 antiarrhythmic drugs), including amiodarone, in 166 (59%) patients. The median follow-up after the last procedure was 48 (19-67) months. Overall, VT-free survival was 69% at 60-month follow-up. Transplant-free survival was 76% and 68% at 60- and 120-month follow-up, respectively. Among the 58 (21%) patients with VT recurrence, CA still resulted in a significant reduction of VT burden, with 31 (53%) patients having only isolated (1-3) VT episodes in 12 (4-35) months after the procedure. At the last follow-up, 128 (45%) patients were only on β-blockers or no treatment, 41 (15%) were on sotalol or class I antiarrhythmic drugs, and 62 (22%) were on amiodarone. Conclusions - In patients with nonischemic dilated cardiomyopathy and VT, endocardial and adjuvant epicardial CA is effective in achieving long-term VT freedom in 69% of cases, with a substantial improvement in VT burden in many of the remaining patients.

Original languageEnglish
Article numbere004328
JournalCirculation: Arrhythmia and Electrophysiology
Issue number10
Publication statusPublished - 1 Oct 2016


  • antiarrhythmic drug
  • catheter ablation
  • dilated cardiomyopathy
  • electroanatomic mapping
  • ventricular tachycardia

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this